Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Show more

21925 W. Field Parkway, Deer Park, IL, 60010-7278, United States

Drug Manufacturers - Specialty & Generic
Healthcare

Market Cap

681.8M

52 Wk Range

$11.09 - $25.99

Previous Close

$25.36

Open

$25.00

Volume

472,326

Day Range

$24.12 - $25.56

Enterprise Value

697M

Cash

25.94M

Avg Qtr Burn

-11.55M

Insider Ownership

4.40%

Institutional Own.

58.71%

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZONISADE (Zonisamide) (ET-104) Details
Rare genetic disease, Neurological disorder

Approved

Update

Approved

Update

Approved

Quarterly sales

EPRONTIA (Topiramate Oral Solution) (ET-101) Details
Tonic-clonic seizures / seizures / migraine

Approved

Quarterly sales

Cysteine hydrochloride injection (generic - ANDA) Details
Additive to amino acid solutions to meet the nutritional requirements of newborn infants

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

ALKINDI® SPRINKLE (hydrocortisone) Details
Adrenocortical Insufficiency (Pediatrics)

Approved

Quarterly sales

Approved

Quarterly sales

Nitisinone Capsules Details
Tyrosinemia type 1, Rare diseases

Approved

Quarterly sales

Biorphen® (phenylephrine HCI) Details
Hypotension (vasodilation in the setting of anesthesia)

Approved

Quarterly sales

Carbaglu® (carglumic acid tablets) Details
Hyperammonemia NAGS deficient, chronic hyperammonemia

Approved

Quarterly sales

KHINDIVI™ (hydrocortisone) Oral Solution Details
Pediatric Adrenocortical Insufficiency

Approved

Quarterly sales

Phase 3

Update

Phase 3

Update

Phase 3

Update

INCRELEX/Mecasermin (Mecasermin) (IGF-1 Agonist) Details
Severe Primary IGF-1 Deficiency Label Expansion

Phase 1

Initiation

Phase 1

Initiation

Phase 1

Initiation

Lamotrigine Oral Suspension (ET-105) Details
Seizures, Epilepsy, Lennox-Gastaut syndrome

Failed

Discontinued

Failed

Discontinued